Recent studies have explored the use of anti-TIGIT antibodies and other immune checkpoint inhibitors to block PVR-mediated immune suppression, which could enhance the efficacy of existing therapies and improve outcomes in high-risk MM patients. The gene discussed is TIGIT; the disease is Miyoshi myopathy.